CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 20, 2011
Result type: Reports
Project Number: SR0264-000
Product Line: Reimbursement Review

Generic Name: Apixaban

Brand Name: Eliquis

Manufacturer: Bristol-Myers Squibb and Pfizer Canada Alliance

Therapeutic Area: Venous thromboembolic events, prevention

Indications: Thromboembolic events, (venous) prevention

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 14, 2012

Recommendation Type: List with clinical criteria and/or conditions